Morebio

Based in Wuhan, China, Morebio is a biopharmaceutical company specializing in peptide-based pharmaceuticals and biotechnology, focusing on innovative drug development and advanced clinical trials. Wuhan Morebio Technology Co. , Ltd. was founded in 2008 in Wuhan, China, and is focused on the research, development, and production of peptide-based biopharmaceuticals.

The company has engaged in one investment deal, with the most recent transaction occurring on March 20, 2025. There is no information available on any subsidiaries or significant pivots in their business strategy. Wuhan Morebio Technology Co. , Ltd.

specializes in the research, development, and production of peptide-based biopharmaceuticals, operating on a fully integrated platform that adheres to GMP standards. Their core offerings include innovative new drugs, particularly those involving Semaglutide and other gene-engineered products. The company also provides a range of cell products, focusing on large-scale industrial production of mesenchymal stem cells and exosomes. Additionally, Morebio develops functional cosmetics, including high-activity peptide acne treatments and vitamin E-based moisturizing creams.

Their CDMO technical services cover peptide drug molecule screening, design, expression, purification, and quality control, catering primarily to pharmaceutical companies and research institutions across global markets, including North America, Europe, and Asia. Wuhan Morebio Technology Co. , Ltd. generates revenue through its diverse product lines and services offered to clients in the pharmaceutical and biotechnology sectors.

The company engages in B2B transactions, partnering with other firms for the development and distribution of peptide drugs and cell products. Revenue is derived from direct sales of flagship products, such as Semaglutide, and contract research and manufacturing services provided to clients seeking customized solutions in drug development. Pricing structures are tailored based on project scope, production volume, and specific client requirements, ensuring flexibility in meeting diverse market needs while enhancing profitability through strategic partnerships and collaborations. In March 2025, Morebio raised an undisclosed amount of venture funding from new investor Jinlan Investment Management.

The company aims to leverage this funding to support the development and launch of new products, including the continued advancement of their Semaglutide product line and exploration of additional peptide therapies. Morebio is also planning to expand into new geographic markets, targeting regions such as North America and Europe by the end of 2026, to enhance their global footprint and partnership opportunities.